Literature DB >> 9468680

Case-control study of childhood leukaemia and cancer in Scotland: findings for neonatal intramuscular vitamin K.

P A McKinney1, E Juszczak, E Findlay, K Smith.   

Abstract

OBJECTIVE: To test the hypothesis of an association between neonatal intramuscular vitamin K and childhood leukaemia and other cancers.
DESIGN: Population based case-control study with data abstracted from hospital records.
SETTING: Scotland.
SUBJECTS: Children aged 0-14 years resident in Scotland from 1991-4 and diagnosed with leukaemia (150), lymphomas (46), central nervous system tumours (79), a range of other solid tumours (142), and a subset of acute lymphoblastic leukaemia (129). Controls were 777 children matched for age and sex, providing 417 matched sets (360 triplets and 57 pairs) for analysis. MAIN OUTCOME MEASURE: Odds ratios for the risk of childhood leukaemia and cancer and intramuscular vitamin K versus a combined group of oral doses, none, and no record. Results are given for information recorded in medical notes and data supplemented by hospital policy.
RESULTS: Odds ratios based on medical record abstractions showed no significant positive association for leukaemias (odds ratio 1.30; 95% confidence interval 0.83 to 2.03), acute lymphoblastic leukaemia (1.21; 0.74 to 1.97), lymphomas (1.06; 0.46 to 2.42), central nervous system tumours (0.74; 0.40 to 1.34), and other solid tumours (0.59; 0.37 to 0.96). There was no association with acute lymphoblastic leukaemia in children aged 1 to 6 years. Imputation of exposure from hospital policy gave similar results. Adjustment for deprivation and type of delivery moved risk estimates closer to unity for all major diagnostic groups.
CONCLUSIONS: The observation of an increased risk of childhood leukaemia and cancer associated with intramuscular vitamin K is not confirmed by this independent population based study.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9468680      PMCID: PMC2665431          DOI: 10.1136/bmj.316.7126.173

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


  12 in total

1.  Six years' experience of prophylactic oral vitamin K.

Authors:  U Wariyar; S Hilton; J Pagan; W Tin; E Hey
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2000-01       Impact factor: 5.747

2.  Communicating risk reductions. Data were selectively used.

Authors:  J McMurray
Journal:  BMJ       Date:  1999-02-27

3.  VITAMIN K ADMINISTRATION IN NEWBORNS - THE CONTROVERSY PERSISTS.

Authors:  C Vidyashankar; S S Bhatia; R K Sharma; R N Mehirishi
Journal:  Med J Armed Forces India       Date:  2017-06-26

Review 4.  Oral versus intramuscular phytomenadione: safety and efficacy compared.

Authors:  R von Kries
Journal:  Drug Saf       Date:  1999-07       Impact factor: 5.606

5.  Vitamin K policies and midwifery practice: questionnaire survey.

Authors:  P Ansell; E Roman; N T Fear; M J Renfrew
Journal:  BMJ       Date:  2001-05-12

Review 6.  Management of epilepsy in women.

Authors:  M D O'Brien; S K Gilmour-White
Journal:  Postgrad Med J       Date:  2005-05       Impact factor: 2.401

7.  A new mixed micellar preparation for oral vitamin K prophylaxis: randomised controlled comparison with an intramuscular formulation in breast fed infants.

Authors:  F R Greer; S P Marshall; R R Severson; D A Smith; M J Shearer; D G Pace; P H Joubert
Journal:  Arch Dis Child       Date:  1998-10       Impact factor: 3.791

Review 8.  Vitamin K in neonates: how to administer, when and to whom.

Authors:  E Autret-Leca; A P Jonville-Béra
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.930

Review 9.  Critical windows of exposure for children's health: cancer in human epidemiological studies and neoplasms in experimental animal models.

Authors:  L M Anderson; B A Diwan; N T Fear; E Roman
Journal:  Environ Health Perspect       Date:  2000-06       Impact factor: 9.031

10.  Vitamin K and childhood cancer: analysis of individual patient data from six case-control studies.

Authors:  E Roman; N T Fear; P Ansell; D Bull; G Draper; P McKinney; J Michaelis; S J Passmore; R von Kries
Journal:  Br J Cancer       Date:  2002-01-07       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.